Literature DB >> 29046393

Rac1-stimulated macropinocytosis enhances Gβγ activation of PI3Kβ.

Zahra Erami1, Bassem D Khalil1, Gilbert Salloum1, Yanhua Yao1, Jaclyn LoPiccolo1, Aliaksei Shymanets2, Bernd Nürnberg2, Anne R Bresnick3, Jonathan M Backer4,5.   

Abstract

Phosphoinositide 3-kinases (PI 3-kinases) are regulated by a diverse range of upstream activators, including receptor tyrosine kinases (RTKs), G-protein-coupled receptors (GPCRs), and small GTPases from the Ras, Rho and Rab families. For the Class IA PI 3-kinase PI3Kβ, two mechanisms for GPCR-mediated regulation have been described: direct binding of Gβγ subunits to the C2-helical domain linker of p110β, and Dock180/Elmo1-mediated activation of Rac1, which binds to the Ras-Binding Domain of p110β. We now show that the integration of these dual pathways is unexpectedly complex. In breast cancer cells, expression of constitutively activated Rac1 (CA-Rac1) along with either GPCR stimulation or expression of Gβγ led to an additive PI3Kβ-dependent activation of Akt. Whereas CA-Rac1-mediated activation of Akt was blocked in cells expressing a mutated PI3Kβ that cannot bind Gβγ, Gβγ and GPCR-mediated activation of Akt was preserved when Rac1 binding to PI3Kβ was blocked. Surprisingly, PI3Kβ-dependent CA-Rac1 signaling to Akt was still seen in cells expressing a mutant p110β that cannot bind Rac1. Instead of directly binding to PI3Kβ, CA-Rac1 acts by enhancing Gβγ coupling to PI3Kβ, as CA-Rac1-mediated Akt activation was blocked by inhibitors of Gβγ. Cells expressing CA-Rac1 exhibited a robust induction of macropinocytosis, and inhibitors of macropinocytosis blocked the activation of Akt by CA-Rac1 or lysophosphatidic acid. Our data suggest that Rac1 can potentiate the activation of PI3Kβ by GPCRs through an indirect mechanism, by driving the formation of macropinosomes that serve as signaling platforms for Gβγ coupling to PI3Kβ.
© 2017 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  G-protein-coupled receptors; Rac; breast cancers; macropinocytosis; phosphoinositide 3-kinase

Mesh:

Substances:

Year:  2017        PMID: 29046393      PMCID: PMC5858185          DOI: 10.1042/BCJ20170279

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  28 in total

Review 1.  Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions.

Authors:  Marie-Pierre Gratacap; Julie Guillermet-Guibert; Valérie Martin; Gaëtan Chicanne; Hélène Tronchère; Frédérique Gaits-Iacovoni; Bernard Payrastre
Journal:  Adv Enzyme Regul       Date:  2010-10-28

2.  Class IA PI3K p110β subunit promotes autophagy through Rab5 small GTPase in response to growth factor limitation.

Authors:  Zhixun Dou; Ji-An Pan; Hashem A Dbouk; Lisa M Ballou; Jennifer L DeLeon; Yongjun Fan; Juei-Suei Chen; Zhimin Liang; Guangpu Li; Jonathan M Backer; Richard Z Lin; Wei-Xing Zong
Journal:  Mol Cell       Date:  2013-02-21       Impact factor: 17.970

3.  Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma.

Authors:  U Maier; A Babich; B Nürnberg
Journal:  J Biol Chem       Date:  1999-10-08       Impact factor: 5.157

4.  PI 3-kinase p110beta: a new target for antithrombotic therapy.

Authors:  Shaun P Jackson; Simone M Schoenwaelder; Isaac Goncalves; Warwick S Nesbitt; Cindy L Yap; Christine E Wright; Vijaya Kenche; Karen E Anderson; Sacha M Dopheide; Yuping Yuan; Sharelle A Sturgeon; Hishani Prabaharan; Philip E Thompson; Gregg D Smith; Peter R Shepherd; Nathalie Daniele; Suhasini Kulkarni; Belinda Abbott; Dilek Saylik; Catherine Jones; Lucy Lu; Simon Giuliano; Sascha C Hughan; James A Angus; Alan D Robertson; Hatem H Salem
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

5.  GPCR Signaling Mediates Tumor Metastasis via PI3Kβ.

Authors:  Bassem D Khalil; Christine Hsueh; Yanyan Cao; Widian F Abi Saab; Yarong Wang; John S Condeelis; Anne R Bresnick; Jonathan M Backer
Journal:  Cancer Res       Date:  2016-03-24       Impact factor: 12.701

6.  Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis.

Authors:  J A Brazzatti; M Klingler-Hoffmann; S Haylock-Jacobs; Y Harata-Lee; M Niu; M D Higgins; M Kochetkova; P Hoffmann; S R McColl
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

7.  Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism.

Authors:  Xuxiao Zhang; Oscar Vadas; Olga Perisic; Karen E Anderson; Jonathan Clark; Phillip T Hawkins; Len R Stephens; Roger L Williams
Journal:  Mol Cell       Date:  2011-03-04       Impact factor: 17.970

8.  G protein-coupled receptor-mediated activation of p110β by Gβγ is required for cellular transformation and invasiveness.

Authors:  Hashem A Dbouk; Oscar Vadas; Aliaksei Shymanets; John E Burke; Rachel S Salamon; Bassem D Khalil; Mathew O Barrett; Gary L Waldo; Chinmay Surve; Christine Hsueh; Olga Perisic; Christian Harteneck; Peter R Shepherd; T Kendall Harden; Alan V Smrcka; Ronald Taussig; Anne R Bresnick; Bernd Nürnberg; Roger L Williams; Jonathan M Backer
Journal:  Sci Signal       Date:  2012-12-04       Impact factor: 8.192

9.  A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Authors:  Zachary A Knight; Beatriz Gonzalez; Morri E Feldman; Eli R Zunder; David D Goldenberg; Olusegun Williams; Robbie Loewith; David Stokoe; Andras Balla; Balazs Toth; Tamas Balla; William A Weiss; Roger L Williams; Kevan M Shokat
Journal:  Cell       Date:  2006-04-27       Impact factor: 41.582

10.  Dissecting the roles of Rac1 activation and deactivation in macropinocytosis using microscopic photo-manipulation.

Authors:  Makoto Fujii; Katsuhisa Kawai; Youhei Egami; Nobukazu Araki
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more
  11 in total

Review 1.  PI3Kβ-A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling.

Authors:  Anne R Bresnick; Jonathan M Backer
Journal:  Endocrinology       Date:  2019-03-01       Impact factor: 4.736

2.  PI3Kβ is selectively required for growth factor-stimulated macropinocytosis.

Authors:  Gilbert Salloum; Charles T Jakubik; Zahra Erami; Samantha D Heitz; Anne R Bresnick; Jonathan M Backer
Journal:  J Cell Sci       Date:  2019-08-16       Impact factor: 5.285

3.  Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells.

Authors:  Ritesh K Srivastava; Changzhao Li; Jasim Khan; Nilam Sanjib Banerjee; Louise T Chow; Mohammad Athar
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-15       Impact factor: 11.205

4.  Roles for 3' Phosphoinositides in Macropinocytosis.

Authors:  Joel A Swanson; Nobukazu Araki
Journal:  Subcell Biochem       Date:  2022

5.  Dorsal ruffles enhance activation of Akt by growth factors.

Authors:  Sei Yoshida; Regina Pacitto; Catherine Sesi; Leszek Kotula; Joel A Swanson
Journal:  J Cell Sci       Date:  2018-11-16       Impact factor: 5.285

6.  LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes.

Authors:  Zhiyong Liu; Enquan Xu; Hien Tran Zhao; Tracy Cole; Andrew B West
Journal:  EMBO J       Date:  2020-08-27       Impact factor: 11.598

Review 7.  The origins and evolution of macropinocytosis.

Authors:  Jason S King; Robert R Kay
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-02-04       Impact factor: 6.237

Review 8.  Macropinocytosis, mTORC1 and cellular growth control.

Authors:  Sei Yoshida; Regina Pacitto; Ken Inoki; Joel Swanson
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

9.  Amplification of PIP3 signalling by macropinocytic cups.

Authors:  Robert R Kay; Thomas D Williams; Peggy Paschke
Journal:  Biochem J       Date:  2018-02-14       Impact factor: 3.857

10.  Rac-GEF/Rac Signaling and Metastatic Dissemination in Lung Cancer.

Authors:  Mariana Cooke; Martin J Baker; Marcelo G Kazanietz
Journal:  Front Cell Dev Biol       Date:  2020-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.